ORIGINAL RESEARCH article
Front. Nutr.
Sec. Clinical Nutrition
Effectiveness and Safety of an Ayurvedic Nutraceutical for Improving Clinical Parameters of Liver Function in Participants with Metabolic Dysfunction-associated Steatotic Liver Disease: A Randomized, Placebo-controlled, Preliminary Phase 2 Exploratory Clinical Trial
Helen Messier 1
Jignesh Patel 2
Vinay Bhomia 2
Dilip Kataria 2
Ghanashyam Patel 3
1. Altum Medical, Orlando, United States
2. Sanjivani Hospital, Gujarat, India
3. Dose, Miami, United States
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) lacks treatment options, with few evidence-based choices beyond lifestyle modification. This is the first clinical study to assess the efficacy of an organic liquid oral nutraceutical composed of turmeric extract, dandelion powder, milk thistle extract, and ginger powder in MASLD. This was a randomized, double-blind, placebo-controlled, preliminary phase 2 exploratory trial conducted at a single center (Sanjivani Super Speciality Hospitals Pvt. Ltd., Gujarat, India) between 7 September 2021 and 25 November 2021. Individuals aged 18–70 years and diagnosed with fatty liver (grades 1–3) were eligible to participate. Participants were randomized 1:1 to receive the test product or placebo, which were both provided as a 60 mL oral solution to be consumed twice daily with a meal for 60 days. The primary endpoint was proportion of participants with improvement in ultrasonography-based fatty liver grading from baseline to Day 60. Fifteen patients each were enrolled in the test product and placebo groups. The mean (standard deviation [SD]) age was 40.6 (10.8) years and 83.3% were male. A significantly higher proportion of patients in the nutraceutical product group had fatty liver grade improvement at Day 60 vs placebo (60.0% [9/15] vs 13.3% [2/15]; p=0.008). Mean (SD) change in fatty liver grading was -0.60 (0.51) and -0.13 (0.35) for test product vs placebo (p=0.007). Adverse events were mild with similar incidence in both groups. The results are limited by the small sample size, single-center design, and short study duration. This study provides preliminary evidence that this organic nutraceutical may improve steatosis grade in individuals with MASLD. Clinical trial registration: Clinical Trial Registry of India (CTRI/2021/08/035359)
Summary
Keywords
dandelion, fatty liver grade, Ginger, metabolic dysfunction-associatedsteatohepatitis, Milk Thistle, oral nutraceutical, turmeric
Received
05 December 2025
Accepted
19 February 2026
Copyright
© 2026 Messier, Patel, Bhomia, Kataria and Patel. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Ghanashyam Patel
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.